GLP-1 Sourcing and Compliance: a Practical Guide for Clinics

Why sourcing is the hard part of a GLP-1 program

If you run a weight-loss, metabolic, or general-wellness clinic, the demand question is already answered. Patients are asking about semaglutide and tirzepatide by name, and if you can't offer a credible program they will buy it somewhere else — often from a direct-to-consumer brand with slick marketing and thin clinical oversight. The hard question for an operator isn't whether to offer GLP-1s. It's how to source them in a way that is legally defensible, clinically sound, and still economically workable.

Sourcing sits at the intersection of three moving parts: the medication itself (branded manufacturer product versus pharmacy-compounded), the pharmacy that dispenses it, and the provider who prescribes it. Get any one of those wrong and the whole program is exposed — to regulatory risk, to supply interruptions, or to the kind of marketing claims that draw enforcement attention. This guide walks through each layer at a high level so you can ask sharper questions of any vendor, including us.

One caveat up front, and it runs through this entire guide: the rules here are federal and state, they interact, and they have changed materially even in the last year. Nothing below is legal advice. Treat it as an operator's orientation, and confirm the specifics for your situation with your prescribing providers and your own legal counsel before you launch or change a program.

Branded vs. compounded: two very different supply chains

There are two fundamentally different ways a GLP-1 reaches your patient, and they carry different rules, costs, and messaging obligations.

Branded (manufacturer) products are FDA-approved drugs made by the original manufacturers — the semaglutide and tirzepatide products you know by their trade names. They come with FDA-approved labeling, established dosing, and manufacturer supply chains. They are also the most expensive path and, at times, the most supply-constrained. When you dispense a branded product, you are dispensing an approved drug and you may describe it as such.

Compounded products are prepared by a licensed compounding pharmacy rather than a manufacturer. Compounding has a legitimate, long-standing role in medicine — for example, to prepare a formulation a patient needs that is not commercially available, or to omit an inactive ingredient a patient is allergic to. Crucially, compounded medications are not FDA-approved, and you must never describe or market them as if they were. They can be an appropriate option in specific clinical circumstances determined by a provider, but they are not a generic, cheaper stand-in for an approved drug, and the legal room to compound them narrows sharply when the approved product is commercially available.

For a clinic operator the practical takeaway is this: branded and compounded are not interchangeable line items you swap for margin. They are different products with different regulatory status, and your intake, your provider workflow, and your marketing all have to reflect which one a given patient is actually receiving. A program that blurs the line — advertising a low compounded price while implying it is the brand-name drug — is exactly the kind of program that gets clinics into trouble.

The shortage window closed — and the ground shifted

Much of the compounded-GLP-1 market that exploded over the past few years existed because of drug shortages. When the FDA lists a drug as being in shortage, federal law gives compounding pharmacies more room to prepare copies of it, because patients otherwise can't get the medication they need. Semaglutide and tirzepatide were both on the shortage list, and a large compounded market grew up around that exception.

That window has largely closed. Over 2025 the FDA determined the tirzepatide and semaglutide injection shortages were resolved and set enforcement deadlines after which routine compounding of copies was no longer covered by that shortage discretion. In broad strokes, once an approved drug is commercially available again, a compounding pharmacy generally may not prepare something that is essentially a copy of it. There remain narrow, patient-specific circumstances where compounding can still be appropriate — for instance a documented clinical need for a formulation, strength, or ingredient profile the commercial product doesn't offer — but those are exceptions a provider and pharmacy have to justify, not a blanket permission.

Why does this matter to you as an operator? Because a program built on the assumption of freely available compounded copies rests on ground that has already moved. The details continue to evolve — deadlines, legal challenges, and state-level positions have all been in flux — so this is precisely the area where you should be verifying current status with your pharmacy partner and counsel rather than relying on last year's playbook. A serious fulfillment partner will be able to tell you exactly what they are dispensing, under what authority, and how that changes as the regulatory picture does.

Sourcing through licensed pharmacies: what to insist on

However you source, the non-negotiables look the same. When you evaluate a fulfillment partner — Heally included — these are the questions worth asking.

Marketing a GLP-1 program you can actually defend

The fastest way to turn a healthy program into a liability is the marketing. GLP-1s sell themselves; the temptation is to over-sell them. Resist it. Your business claims — that you can offer a competitively priced program, launch quickly, serve patients across states — are yours to make. The medical claims are where clinics get into trouble.

Three rules will keep you on the right side of the line. First, never promise clinical outcomes. "Lose 20 pounds," "guaranteed results," and "melt fat fast" are outcome promises; they are also the phrases most likely to draw scrutiny. Describe the program and the process, not a guaranteed result. Second, never imply FDA approval for a compounded product. If any part of your program dispenses compounded medication, your marketing cannot suggest patients are getting an FDA-approved drug. Third, don't bury the provider's role. Your messaging should make clear that a licensed provider evaluates each patient and decides what, if anything, is appropriate — not that anyone who clicks "buy" gets a prescription.

Good compliant marketing is not weak marketing. It leans on what is genuinely differentiating: a real clinical relationship, a licensed and traceable supply chain, responsive support, and honest pricing. Patients who have been burned by fly-by-night sellers actually value that credibility. If you want to see how this ties into building a branded storefront, our white-label GLP-1 weight-loss brand and weight-loss clinic pages walk through the operator side in more depth.

Provider responsibility is the foundation, not a footnote

Everything above — the sourcing, the pharmacy relationship, the marketing — sits on top of a clinical decision made by a licensed provider. That ordering is not a formality. The provider evaluates the patient, determines eligibility, decides whether a GLP-1 is appropriate at all, selects the product and dose, and owns the ongoing clinical relationship including titration, monitoring, and managing side effects.

For an operator, this has a concrete implication: your program has to be built so the provider decision comes first and everything else follows. Intake collects the clinical information the provider needs. The provider reviews it in a real evaluation. Only then does a prescription generate, and only then does the pharmacy fill. A program that inverts that order — that treats the provider sign-off as a checkbox after the patient has effectively already bought the drug — is both clinically and legally fragile.

This is also where the 50-state provider network matters for clinics that don't employ prescribers in every state. If you have your own providers, coverage follows their licensure. If you don't, a network of board-certified providers lets you serve patients across states while keeping the clinical decision exactly where it belongs. Either way, the principle holds: prescribing and eligibility decisions rest with the licensed provider, and your job as the operator is to give them the workflow and information to make good ones.